Omicron is here the new test that measures immunity against the virus and the effectiveness of the vaccine in less than 24 hours

A new blood test is able to measure our immunity to the Covid virus and the effectiveness of the vaccine in less than 24 hours. Rather than assessing antibodies, it identifies the activation of T lymphocytes, champions of the adaptive immune response (resulting from infection or vaccination) that help protect us from the most severe forms of disease. The test, which can also be widely applied to assess population immunity and vaccine efficacy, can help identify those most vulnerable who need booster doses. This is indicated by the study published in Nature Biotechnology by an international team led by Ernesto Guchion of the Tisch Cancer Institute at Mount Sinai in New York and Antonio Bertoletti of Duke-NUS Medical School in Singapore.

Omicron, the new blood test

“The test we created has the potential to measure population cellular immunity and test the efficacy of new vaccines at large scale,” says Guchion. “We know that vulnerable people do not always develop an antibody response, so measuring T-cell activation is critical to assessing the true extent of a person’s immunity. Furthermore, the emergence of variants such as Omicron, which largely escape the neutralizing ability of antibodies,” points out To the need for tests able to measure T-lymphocytes, which are more effective against emerging variants of concern.”

T lymphocytes

The new test assesses the ability of T lymphocytes in the blood to respond to a series of peptides that normally encapsulate various proteins in the SarsCoV2 virus, including Spike. “The ability to use different combinations of peptides – confirms Jordi Ochando of the Tisch Cancer Institute – our approach represents a flexible strategy that can easily be implemented to detect the presence of T cells that respond to different viral proteins. These T cells play an important role in protecting against emerging mutant strains, so we can Instantly measure the effect of viral mutations on cellular immunity.The test recently received European CE-IVD certification (in vitro diagnostics), while clinical validation is underway by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Leave a Comment